Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Scientific: Pipeline Will Aid Return To Growth By Year End

This article was originally published in The Gray Sheet

Executive Summary

Potential growth drivers identified by the firm during its April 19 first-quarter earnings call include the Ingenio family of pacemakers and BSX-manufactured Promus Element everolimus-eluting stent system.

You may also be interested in...



Earnings Calls In Brief

Johnson & Johnson’s mid-year Synthes purchase drives third-quarter revenue growth. Abbott spin-off on track. More news briefs.

New Products In Brief

Recent product approvals and launches include St. Jude’s Assura and Ellipse ICDs, Boston Scientific’s Ingenio pacemakers and Medtronic’s Valiant Captivia thoracic stent graft system.

New Products In Brief

The latest product approvals and launches in cardiology, ophthalmology and more.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT031149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel